BIOMAT Database Logo BIOMAT Database Logo

Peptides and peptidomimetics as a therapeutic candidate for the treatment of COVID-19: A brief review. 2023

J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Department of Pharmacology, PGIMER, Chandigarh, India.

Novel SARS-CoV-2 (COVID-19) is affecting worldwide as declared pandemic by the WHO. Various repositioning and novel therapeutic agents are being evaluated under different clinical setups; however, there is no promising therapeutic agent reported to date. Small molecules like peptides have their popularity as their specificity, delivery, and synthesizability as promising therapeutic agents. In this study, we have reviewed the published literature describing peptide designing, in silico binding mode, antiviral activity, preventive measures, and in vivo assessments. Here, we reported all the results which are promising against SARS-CoV-2 as therapeutic and preventive (vaccine candidates), and their status in the drug development process.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D057786 Peptidomimetics Compounds that are designed to mimic the 3D structure of a natural peptide or protein. Peptidomimetic
D058492 Drug Repositioning The deliberate and methodical practice of finding new applications for existing drugs. Drug Repurposing,Drug Rescue,Repositioning, Drug,Repurposing, Drug,Rescue, Drug

Related Publications

J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Peptides and peptidomimetics as therapeutic agents for Covid-19.
January 2022, Peptide science (Hoboken, N.J.),
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment.
January 2023, Clinical drug investigation,
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Therapeutic peptides and peptidomimetics.
August 1997, Current opinion in biotechnology,
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Naltrexone a potential therapeutic candidate for COVID-19.
February 2022, Journal of biomolecular structure & dynamics,
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19.
December 2020, Pharmaceuticals (Basel, Switzerland),
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Lithium as a candidate treatment for COVID-19: Promises and pitfalls.
November 2020, Drug development research,
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics.
September 2020, Future medicinal chemistry,
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19).
November 2020, Chinese medical journal,
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Budesonide: A promising candidate therapeutic for early COVID-19.
August 2021, Annals of medicine and surgery (2012),
J Kumaravel, and Harvinder Singh, and Sukhmeet Kaur, and Ajay Prakash, and Bikash Medhi
Erythropoietin as candidate for supportive treatment of severe COVID-19.
June 2020, Molecular medicine (Cambridge, Mass.),
Copied contents to your clipboard!